Dapagliflozin Metformin in T2D: Six Potential Benefits Beyond Glucose Lowering-Dr Setu Gupta

While dapagliflozin-metformin dual fixed-dose combinations (FDCs) are increasingly used in type 2 diabetes (T2D) management, their complementary mechanisms of action extend far beyond glycemic control. The combination works through distinct pathways: dapagliflozin targets renal glucose excretion and mitophagy (removal of dysfunctional mitochondria), while metformin enhances hepatic insulin sensitivity and modulates gut-mediated signals; more recently, a central glucose-regulating action of metformin has also been reported.

These mutually supporting actions deliver six distinct benefits: weight management, blood pressure reduction, cardiovascular protection, renal preservation, hepatic fat reduction, and multi-organ protection, each supported by mechanistic and real-world evidence. This brief review article examines each of these benefits of the dapagliflozin metformin combination & its clinical relevance in the context of comprehensive cardiometabolic care in T2D.

The six benefits of the dapagliflozin metformin combination beyond glucose-lowering include:

Benefit 1: Weight Reduction

Dapagliflozin reduces body weight through sodium–glucose co-transporter-2 (SGLT2) inhibition, which decreases renal glucose reabsorption and increases urinary glucose excretion. In overweight and obese adults with T2DM, dapagliflozin achieves significant weight reduction of 2–3 kg, with effects sustained over 12 months in real-world settings and up to 4 years in long-term follow-up.[1] Metformin contributes additional weight loss of 2–3 kg, mediated via hypothalamic appetite regulation and gut microbiome modulation. The dapagliflozin- metformin combination targets weight reduction through complementary insulin-independent pathways, providing durable efficacy.[2]

Benefit 2 Blood Pressure Lowering Effect

Dapagliflozin lowers blood pressure through dual mechanisms: osmotic and natriuretic diuresis during early treatment, followed by long-term sympathetic overdrive suppression.[3] In a randomized, double-blind, placebo-controlled trial of 449 patients with T2D and hypertension on background ACE inhibitor or ARB therapy, dapagliflozin 10 mg reduced seated systolic blood pressure from a baseline of 151.0 mmHg by 11.90 mmHg, demonstrating significant blood pressure lowering in this population.

Metformin also contributes additional blood pressure lowering via sodium–chloride co-transporter phosphorylation and renal sodium excretion. Dapagliflozin–metformin combination provides synergistic blood pressure reduction through complementary diuretic and sodium-regulatory pathways.[4]

Benefit 3 Cardiovascular Protection & Outcomes

Dapagliflozin activates AMP-activated protein kinase (AMPK-α2), promoting mitophagy, selective elimination of dysfunctional mitochondria, reducing cardiac hypertrophy and improving cardiac function beyond glycemic control.[5] In 1,430 PCI patients, dapagliflozin significantly reduced periprocedural myocardial infarction (39.77% vs 60.23%; adjusted OR 0.436; p<0.001).[6] Metformin provides cardioprotection through AMPK activation and suppression of pro-inflammatory pathways, independent of glucose lowering. Landmark UK Prospective Diabetes Study (UKPDS) data demonstrated metformin reduces the relative risk of all-cause mortality by 36% and diabetes-related mortality by 42%, with sustained effects over 10 years. Dapagliflozin metformin combination have the potential for synergistic cardiovascular protection through complementary cellular and metabolic actions.[7]

Benefit 4 Renal Preservation & Protection

Dapagliflozin protects kidneys through PI3K-AKT pathway activation, reducing ischemia-reperfusion injury, inflammation, and apoptosis.[8] In the DAPA-CKD trial (n=4,304), dapagliflozin reduced the composite outcome of ≥50% glomerular filtration rate (GFR) decline, end-stage renal disease (ESRD), or renal/cardiovascular death (HR 0.61; p<0.001) and all-cause mortality (4.7% vs 6.8%; p=0.004).[9] Metformin provides AMPK-mediated renal protection by reducing podocyte loss and mesangial apoptosis, with meta-analysis showing reduced ESRD (HR 0.61) and all-cause mortality (HR 0.76).[10] Combined SGLT2i-metformin therapy has demonstrated superior kidney outcomes (aHR 0.65) and mortality reduction (aHR 0.74) versus SGLT2i monotherapy.[11]

Benefit 5 Hepatic Steatosis Reduction

Dapagliflozin reduces hepatic steatosis by decreasing lipogenic enzymes and inducing fatty acid oxidation via AMPK-mammalian target of rapamycin (mTOR) pathway activation.[12] RCT data (n=56) showed dapagliflozin reduced liver magnetic resonance imaging proton density fat fraction (MRI-PDFF) by 3.7% versus placebo (+0.5%, p=0.001), independent of weight loss.[13]Metformin reduces hepatic steatosis through AMPK-mediated suppression of lipogenic genes.[14] In a prospective 120-day study of Asian Indian patients with T2D, dapagliflozin (n=30) reduced hepatic fat fraction from 15.16% to 10.06% (p=0.0001) and pancreatic fat from 11.52% to 8.99% (p=0.008). Both metformin (n=15) and dapagliflozin significantly lowered hepatic fibrosis and Fetuin-A, a hepatokine secreted by the liver that acts as a natural inhibitor of the insulin receptor, by 87.6 μg/mL (p=0.0001), providing comprehensive hepatic protection.[15]

Benefit 6 Pleiotropic Effects

Dapagliflozin reduced worsening heart failure events by 30% and cardiovascular death by 18%, irrespective of diabetes status, and dapagliflozin delayed projected time to kidney failure by 6.6 years versus standard therapy (25.2 vs 18.5 years).[16,17] Dapagliflozin significantly reduced systemic inflammatory indices from baseline, as shown in a prospective study (n=191 heart failure patients), with Systemic Immune–Inflammation Index (SII) decreasing from 1357.4 to 805.8 (p < 0.001) and Systemic Inflammation Response Index (SIRI) from 3.68 to 2.19 (p < 0.001).[18] Metformin also serves a dual role in both managing hyperglycemia and reducing cardiovascular risk, with a study reporting reduced acute MI relative risk by 24% in patients with T2DM (HR 0.76, 95% CI 0.41–0.96).[19]Metformin reduced Major Adverse Cardiovascular Events (MACE) risk by 24% (IRR 0.76, 95% CI 0.64–0.92) and Major Adverse Kidney Events (MAKE) risk by 55% (IRR 0.45, 95% CI 0.33–0.62) in patients with T2DM, with consistent benefits across CKD stages 3A. [20]

Figure: Benefits of Dapagliflozin + Metformin in T2D

Key Takeaways

Beyond glycemic control, the dapagliflozin–metformin combination delivers complementary multi-organ cardiometabolic protection, supporting weight, blood pressure, cardiovascular, renal, and hepatic health in T2D.

Abbreviations: AMPK = AMP-activated protein kinase, AMPK-α2 = AMP-activated protein kinase alpha-2, BP = Blood pressure, DAPA-CKD = Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease trial, ESRD = End-stage renal disease, GFR = Glomerular filtration rate, IBD = Inflammatory bowel disease, iNOS = Inducible nitric oxide synthase, MACE = Major Adverse Cardiovascular Events, MAKE = Major Adverse Kidney Events, mTOR = Mammalian target of rapamycin, MI=Myocardial Infarction, MRI-PDFF = Magnetic resonance imaging proton density fat fraction, NO = Nitric oxide, PCOS/PMOS = Polycystic ovary syndrome/Polyendocrine Metabolic Ovarian Syndrome, PCI = Percutaneous coronary intervention, RCT = Randomized controlled trial, SGLT2 = Sodium-glucose co-transporter-2, SGLT2i = SGLT2 inhibitor, T2D = Type 2 diabetes, SII = Systemic Immune–Inflammation Index, SIRI = Systemic Inflammation Response Index, TSH = Thyroid-stimulating hormone, UKPDS = UK Prospective Diabetes Study